Skip to main content
John Routes, MD, Allergy & Immunology, Milwaukee, WI

JohnM.RoutesMD

Allergy & Immunology • Milwaukee, WI

Clinical & Laboratory Immunology

Professor Emeritus of Pediatrics, Medicine, Microbiology and Molecular Genetics

Join to view full profile

Dr. Routes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Routes' full profile

Already have an account?

Summary

  • Dr. Routes graduated from Indiana University School of Medicine, and received his Internal Medicine training at the University of Utah, Fellowship training in Allergy and Clinical Immunology at National Jewish Health and the University of Colorado School of Medicine, where he was a faculty member for over twenty years. In 2006, he became head of the Allergy and Clinical Immunology Division in the Department of Pediatrics at Medical College of Wisconsin (MCW) and established the Primary Immunodeficiency Program at MCW. In 2008, Dr. Routes was the principal investigator for the first statewide program (Wisconsin) to screen all newborns for severe combined immunodeficiency (SCID). In 2010, Dr. Routes testified at the HHS subcommittee, the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children, on Wisconsin’s successful, statewide implementation of newborn screening of infants with SCID, which resulted in the addition of SCID to the recommended panel of newborn screening tests by the United States government. He also has a longstanding interest in lung disease in primary immunodeficiencies and was the corresponding author describing granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiencies as a unique disease, which is distinct from sarcoidosis. He subsequently has published on the successful use of immunosuppressive therapy to treat this disorder. He has been a reviewer on several NIH study sections and served as Chair of the NIH Study Section “Investigations on Primary Immunodeficiencies”. Dr. Routes was elected as President of the Clinical Immunology Society (CIS) in 2012-2013 and in 2016 received the CIS Distinguished Service Award.

Education & Training

  • University of Colorado School of Medicine/National Jewish Health (Adult)
    University of Colorado School of Medicine/National Jewish Health (Adult)Fellowship, Allergy and Immunology, 1985 - 1989
  • University of Utah Health
    University of Utah HealthResidency, Internal Medicine, 1981 - 1984
  • Indiana University School of Medicine
    Indiana University School of MedicineClass of 1981

Certifications & Licensure

  • WI State Medical License
    WI State Medical License 2006 - 2023
  • CO State Medical License
    CO State Medical License 1985 - 2009
  • UT State Medical License
    UT State Medical License 1982 - 1990
  • American Board of Allergy and Immunology Allergy & Immunology
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Fellow Clinical Immunology Society Clinical Immunology Society, 2022
  • America's Top Doctors Castle Connolly, 2009-2022
  • Best Doctors Best Doctors, Inc., 2007-2022
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency  
    James W. Verbsky, MD, Mary K. Hintermeyer, RN, APNP, Pippa M. Simpson, PhD, Mingen Feng, MS, Jody Barbeau, BS, Nagarjun Rao, MD,e Carlyne D. Cool, MD, Luis A. Sosa-Loz..., Journal Allergy Clinical Immunology, 2/7/2021

Other

Grant Support

  • GLILD in CVIDNational Institute of Allergy and Infectious Diseases (NIAID)2014–Present
  • Jeffrey Modell Diagnostic and Research Center for Primary ImmunodeficienciesJeffrey Modell Foundation2009–2022
  • Lymphoproliferative Disorders In Primary ImmunodeficienciesNational Cancer Institute2008–2012
  • Anti-Tumorigenic Activity Of Adenovirus E1ANational Cancer Institute2007–2011
  • AMID In Apoptosis And P53-Mediated Downstream EffectsNational Cancer Institute2005
  • Dissimilar Immunogenicities Of ELA And E7 OncoproteinsNational Cancer Institute1998–2002
  • Examining Helicobacter Pylori Gastric Infection In Patients With ImmunodeficenncyNational Center For Research Resources1997
  • Viral Oncogenes, Interferon, And ImmunityNational Institute Of Allergy And Infectious Diseases1992–1996

Committees

  • Co-Chairman, World Allergy Organization Special Committee on Immunodeficiency 2013 - Present
  • Consultant and Voting Member, FDA Medical Devices Panel 2012 - Present
  • Member, NIH: Loan Repayment Program 2010 - Present
  • Member, NIH Study Section-Investigations in Primary Immunodeficiency 2009 - Present
  • Consultant and Voting Member, FDA Immunology Devices Panel 2006 - Present
  • Chairman, NIH Study Section-Investigation in Primary Immunodeficiency 2017 - 2020
  • Chairman, NIH Study Section:Opportunities for Collaborative Research @NIH Clinical Center 2013 - 2013

Professional Memberships

External Links

Dr. John Routes, Dr. John Routes, MD, Dr. J Routes, Dr. John M. Routes